- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07869355
BRE-13: Mediterranean Diet (BRE-13)
BRE-13: Mediterranean Diet-A Presurgical Window of Opportunity Trial Among Women With Breast Cancer
Explore the effect of MedDiet vs. Usual Diet on circulating and breast tumor fatty acid profiles. The investigators aim to examine impact on tumor biology in newly diagnosed participants.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
- Kosttilskudd: Explore the effect of MedDiet vs. Usual Diet on Fatty Acid Profile
- Diagnostisk test: Explore the effect of MedDiet vs. Usual Diet on Breast Tumor Tissue
- Diagnostisk test: Explore the effect of MedDiet vs. Usual Diet on Lipids
- Diagnostisk test: Explore the effect of MedDiet vs. Usual Diet on tumor tissue expression
Detaljert beskrivelse
Conduct a 3-week presurgical window trial among 30 women with stage I-III luminal breast cancer. Participants will be randomized 1:1 to a controlled MedDiet or an enhanced usual-care control. This study will generate critical translational data on how dietary fat composition influences tumor metabolism and immune response, informing future diet-based cancer interventions.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Lisa Marie Tussing-Humphreys, Ph.D.
- Telefonnummer: 312 355 5521
- E-post: tussing@uic.edu
Studer Kontakt Backup
- Navn: Meredith Russell
- Telefonnummer: 312 355 5112
- E-post: mrussel3@uic.edu
Studiesteder
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60612
- Rekruttering
- University of Illinois at Chicago Campus
-
Ta kontakt med:
- Meredith Russell, BS
- Telefonnummer: 312 355 5112
- E-post: mrussel3@uic.edu
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age ≥ 18 years;
- Newly diagnosed stage I-III luminal breast cancer
- Planned surgical resection at UI Health
- Ability to speak, read, write, and understand English
- A Mediterranean Eating Pattern for Americans (MEPA-III) score <13 indicating that they do not currently follow a MedDiet;
- ECOG performance status of 0 or 1.
Exclusion Criteria:
- Currently following a MedDiet, vegan diet, or dietary restrictions (e.g., religious, food intolerance/allergy) that preclude adoption of a MedDiet;
- Lack of access to a space to safely store and reheat foods items;
- Living in facility that provides meals;
- Chronic CKD stage 3+ or currently receiving dialysis treatment;
- History of GI surgery involving removal of part of the stomach or intestines;
- Type 1 or Type 2 diabetes;
- Autoimmune or Inflammatory disease or immunocompromised; and
- Cachexia.
We will not exclude other neoadjuvant treatments. Adults unable to consent Individuals who are not yet adults (infants, children, teenagers) Pregnant or breastfeeding women Prisoners
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Med Diet
Mediterranean Diet (MedDiet) is a dietary pattern characterized by a low intake of saturated fats and a high intake of unsaturated fats, with olive oil as the primary culinary fat (7, 8). |
Fatty acid profile (chain length and degree of saturation) in circulation of blood, tumor tissue, and tumor interstitial fluid. Fatty acid profile (chain length and degree of saturation) in breast tumor tissue. Lipid availability in blood, tumor tissue, and tumor interstitial fluid. Tumor tissue will explore the effect of MedDiet vs. Usual Diet on tumor proliferation (Ki67) and expression of NK and CD8 T cells and chylomicrons (Apo48 staining). |
|
Ingen inngripen: Usual Diet
Dietary fat and cancer has been conducted in preclinical models of diet-induced obesity, where high-fat diets promote tumor growth |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Aim 1a
Tidsramme: 3 weeks
|
Fatty acid profile (chain length and degree of saturation) in blood. |
3 weeks
|
|
Aim 1b
Tidsramme: 3 weeks
|
Lipid availability in blood, tumor tissue, and interstitial fluid. |
3 weeks
|
|
Aim 1c
Tidsramme: 3 weeks
|
Fatty acid profile (chain length and degree of saturation) in breast tumor tissue, |
3 weeks
|
|
Aim 2a
Tidsramme: 3 weeks
|
peripheral blood monocyte cells from the electronic health record. |
3 weeks
|
|
Aim 2b
Tidsramme: 3 weeks
|
Tumor tissue will explore the effects on tumor proliferation (Ki67) cells. |
3 weeks
|
|
Aim 2c
Tidsramme: 3 weeks
|
Tumor tissue will explore the effects on expression of NK cells. |
3 weeks
|
|
Aim 2d
Tidsramme: 3 weeks
|
Tumor tissue will explore the effects on CD8 T cells(immunohistochemistry) cells. |
3 weeks
|
|
Aim 2e
Tidsramme: 3 weeks
|
Tumor tissue will explore the effects on chylomicrons (Apo48 staining) cells. |
3 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Exploratory aim a
Tidsramme: 3weeks
|
Stool will be used to analyze gut microbiome changes using shotgun bioinformatics and downstream bioinformatics to study compositional and metabolic changes among the two study arms. |
3weeks
|
|
Exploratory aim b
Tidsramme: 3weeks
|
Stool will be used to analyze downstream bioinformatics to study compositional and metabolic changes among the two study arms. |
3weeks
|
|
Exploratory aim c
Tidsramme: 3weeks
|
Stool will be used to analyze metabolic changes among the two study arms. |
3weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Lisa Marie Tussing-Humphreys, Ph.D, University of Illinois Chicago Campus
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2026-0573
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .